Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly
Sydney B Long, Michael J Blaha, Roger S Blumenthal, Erin D MichosJohns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USAAbstract: Age is one of the strongest predictors of cardiovascular disease (CVD) risk. Treatment with statins can significantly reduce CVD events and...
Saved in:
Main Authors: | Sydney B Long, Michael J Blaha, Roger S Blumenthal, et al |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2010
|
Subjects: | |
Online Access: | https://doaj.org/article/25d874b81cfd479a9b2df6b1d957b634 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Statins in the primary prevention of cardiovascular disease. Rosuvastatin capabilities
by: Marina G. Bubnova, et al.
Published: (2021) -
Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry
by: Michael G. Nanna, et al.
Published: (2018) -
SIMULTANEOUS DETERMINATION OF ENALAPRIL AND STATIN'S IN PHARMACEUTICAL FORMULATIONS BY RP-HPLC
by: SULTANA,NAJMA, et al.
Published: (2011) -
Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin
by: Wang Z, et al.
Published: (2013) -
SIMULTANEOUS DETERMINATION OF CEFTRIAXONE SODIUM AND STATIN DRUGS IN PHARMACEUTICAL FORMULATIONS AND HUMAN SERUM BY RP-HPLC
by: SULTANA,NAJMA, et al.
Published: (2010)